RxDoctor Payments Data

Heather Kessler-Reyes, MD

Pulmonary Disease · Boca Raton, FLNPI 1760700348

Payments from drug & device makers

$8,046in general payments, 2019–2025

Across 182 payments — averaging $44.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • AstraZeneca$846
  • GSK$609
  • Boehringer Ingelheim$590
  • Mylan Specialty L.p.$256
  • Actelion Pharmaceuticals US, Inc.$224
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$1,41518%
  • Food & beverage$3,97049%
  • Education$2,66233%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,046 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$253,862
Medicare patients
911
Services billed
2,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter177$165,153
Breztri AerosphereBudesonide/Glycopyr/Formoterol63$58,068
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$30,014
Breo ElliptaFluticasone/Vilanterol42$21,559
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$15,449
Albuterol Sulfate HfaAlbuterol Sulfate125$3,256
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,218
Wixela InhubFluticasone Propion/Salmeterol24$2,475
Azelastine Hcl20$743
Montelukast Sodium88$722
Prednisone74$350
Methylprednisolone43$271
Mometasone Furoate12$262
Azithromycin33$169
Fluticasone Propionate18$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$609$216,726274 claims
AstraZenecaBreztri Aerosphere$846$58,06863 claims
Boehringer IngelheimStiolto Respimat$590$15,44918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →